Table 2 TEAEs in >1 patient by system organ class
System organ class, na (%) | Placebo (n = 9) | Namilumab 150 mg (n = 8) | Namilumab 300 mg (n = 7) | Total (N = 24) |
|---|---|---|---|---|
Preferred term, na (%) | ||||
Any TEAE | 5 (56) | 5 (63) | 4 (57) | 14 (58) |
Musculoskeletal and connective tissue disorders | 3 (33) | 3 (38) | 0 | 6 (25) |
 Exacerbation/worsening of RA | 2 (22) | 1 (13) | 0 | 3 (13) |
 Musculoskeletal pain | 0 | 2 (25) | 0 | 2 (8) |
 Pain in extremity | 1 (11) | 0 | 0 | 1 (4) |
 Muscular weakness | 1 (11) | 0 | 0 | 1 (4) |
Laboratory investigations (total)b | 1 (11) | 3 (38) | 2 (29) | 6 (25) |
Infections and infestations | 2 (22) | 3 (38) | 0 | 5 (21) |
 Nasopharyngitis | 2 (22) | 2 (25) | 0 | 4 (17) |
 Urinary tract infection | 0 | 1 (13) | 0 | 1 (4) |
Gastrointestinal disorders | 0 | 2 (25) | 1 (14) | 3 (13) |
 Abdominal pain, upper | 0 | 1 (13) | 0 | 1 (4) |
 Diarrhea | 0 | 1 (13) | 0 | 1 (4) |
 Abdominal pain | 0 | 0 | 1 (14) | 1 (4) |
Cardiac disorders | 1 (11) | 1 (13) | 0 | 2 (8) |
 Bradycardia | 1 (11) | 0 | 0 | 1 (4) |
 Coronary artery stenosis | 0 | 1 (13) | 0 | 1 (4) |
General disorders and administrative site conditions | 1 (11) | 0 | 1 (14) | 2 (8) |
 Chest discomfort | 1 (11) | 0 | 0 | 1 (4) |
 Chest pain | 0 | 0 | 1 (14) | 1 (4) |
 Influenza-like illness | 0 | 0 | 1 (14) | 1 (4) |
Nervous system disorders | 1 (11) | 1 (13) | 0 | 2 (8) |
 Paresthesia | 0 | 1 (13) | 0 | 1 (4) |
 Somnolence | 1 (11) | 0 | 0 | 1 (4) |
Renal and urinary disorders | 1 (11) | 0 | 1 (14) | 2 (8) |
 Dysuria | 1 (11) | 0 | 0 | 1 (4) |
 Nephrolithiasis | 0 | 0 | 1 (14) | 1 (4) |